Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Ties Up with Tokyo University Venture for New Drug Candidate Exploration
September 28, 2012
- Eisai, Santen Conclude Option Agreement in Ophthalmologic Field
September 27, 2012
- Over 50,000 Patients Treated with Eli Lilly’s Forteo in 2 Years since Launch
September 27, 2012
- Kyowa Kirin Takes Full Control of South Korean Subsidiary
September 27, 2012
- GSK Files NDA for ICS/LABA Combination Drug for Asthma, COPD in Japan
September 27, 2012
- Santen to Establish New Sales and Marketing Subsidiary in China
September 27, 2012
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
- Janssen Pharmaceutical Files for Once-Monthly Schizophrenia Treatment in Japan
September 26, 2012
- Kyowa Pharmaceutical Voluntarily Recalls Allopurinol Tablets 100 mg
September 25, 2012
- Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
- Equa Tops Both GP, HP Markets in August: RepTrack Survey
September 24, 2012
- Most Top Drugstore Chains Plan to Continue Dispensing Point Services After October
September 24, 2012
- Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo
September 24, 2012
- Novartis to File for Additional Indication for Lucentis in Japan within This Year
September 24, 2012
- Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…